Rodrigo Souza

Biocatalysis and Organic Synthesis Group, Chemistry Institute, Federal University
of Rio de Janeiro, Rio de Janeiro, Brazil

Zavegepant (zavzpret) is a calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine sold by Pfizer and approved by the FDA on march 2023. Migraine is a severe pulsating headache of moderate to severe pain intensity, often associated with nausea or vomiting, phonophobia, and photophobia. Attacks can last from four to 72 hours. Zavegepant belongs to the class of drugs called CGRP receptor antagonists. CGRP receptor antagonists work to treat migraine by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide which is thought to play a causal role in migraine. Zavegepant may provide an important alternative for patients who need a quick onset of action or those who cannot take oral treatments due to nausea and vomiting at the time of migraine onset. This molecule was a key part of a recent acquisition by Pfizer (BioHaven, 11.6Bi USD) where they were looking to the future growth on company’s portfolio of migraine medicines. The deal handed Pfizer rights to rimegepant, a pill for migraine prevention and treatment, as well as zavegepant and other preclinical studies. In January, the comp ...